Everything you need to know about Growth Hormone Releasing Hormone research
Tesamorelin is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog. It was FDA-approved under the brand name Egrifta for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
Unlike growth hormone-releasing peptides (GHRPs) that work through the ghrelin pathway, Tesamorelin works directly through GHRH receptors, providing a more physiological stimulation of the pituitary gland's growth hormone secretion.
Directly stimulates the pituitary gland's somatotroph cells to release growth hormone through GHRH receptor binding.
Increases insulin-like growth factor-1 (IGF-1) levels, which mediates many of growth hormone's effects on tissues.
Produces a more natural GH release pattern compared to GHRPs, mimicking the body's own growth hormone secretion.
Research shows reduction in visceral adipose tissue, particularly abdominal fat, through increased GH levels.
Research Use Only: This product is intended exclusively for laboratory research purposes. Not for human consumption. All research must be conducted in controlled laboratory settings by qualified personnel in accordance with applicable laws and regulations.
